EKSO BIONICS HOLDING (OTCBB:EKSO) announced that Amy Wendell who was former Senior VP of segment “Strategy and Business Development” with Covidien plc (NYSE:COV) has been elected to the company’s Board. The Co-Founder and CEO Nathan Harding said that Amy Wendell in her previous association with reputed firm Covidien had successfully completed numerous acquisition plans.
She concluded acquisition of more than hundred firms in healthcare segments. Wendell is proficient with the dynamics of the healthcare industry and plans the strategies that support the growth plans of the company. The company intends to benefit substantially from her strong experience and expertise in the respective field.
The expert view
Steven Sherman who is the Chairman of EKSO said that the company wanted to elect a board member with all the major traits that Wendell mirrors for more than a year now. The management is thrilled to have such an experienced person on the board. The Chairman further added that he is confident Wendell will notably contribute in the growth of the organization.
Expressing her views on her recent role, Wendell said that she was always included towards medical device technology. In the past she had guided several firms to achieve their growth plans in order to have a positive impact on people’s lives. She will continue with her efforts to help companies reach their milestones and venture into new markets. She is excited with the accomplishments of EKSO.
Wendell handled a number of business development plans like Mergers and acquisitions, distribution, licensing, integrations, divestitures, market intelligence and equity investments. After the recent addition, the size of board now stands at seven.
In last trading session, the share price of EKSO declined more than 3% to close the trading session at $1.63. The decline came at a share volume of 341,773 much lower than average volume of 1.06 million.